United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 1

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderGilead · 65

Strongest available pathExelixis · +188.3%

Widest latest marginExelixis · 33.7%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GILD · Nasdaq

Gilead

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Palo Alto, California$180.64B market cap

View full Companies Radar profile

65Solid

Snapshot price$145.7as of page date

Monthly-close return+104.5%five-year window

FY2025 revenue$29.44BGILEAD SCIENCES, INC.

Net margin28.9%FY2025

P/E snapshot14.7xone ratio, not a verdict

Prism attention34.6%share across these five

Filing track recordRevenue, USD billions

+7.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%

52-week position76% through range

$108.5$157.3

News mentions45.0K

Community mentions8.1Kpartial coverage

U.S.-scope patents13744

Prism InsightsWhat sits behind the readiness signal
Observed risk 8/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position52/100
Capital-event signal90/100
Innovation pulse22/100

Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 96 M&A involvements, 13 asset-acquisition events and 40 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EXEL · Nasdaq

Exelixis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1994San Francisco, California$13.49B market cap

View full Companies Radar profile

58Moderate

Snapshot price$54.45as of page date

Monthly-close return+188.3%five-year window

FY2025 revenue$2.32BEXELIXIS, INC.

Net margin33.7%FY2025

P/E snapshot17.1xone ratio, not a verdict

Prism attention1.9%share across these five

Filing track recordRevenue, USD billions

+61.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%

52-week position87% through range

$33.76$57.57

News mentions2.5K

Community mentions0partial coverage

U.S.-scope patents2645

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position15/100
Capital-event signal80/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 2 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3NBIX · Nasdaq

Neurocrine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1992San Diego, California$15.66B market cap

View full Companies Radar profile

57Moderate

Snapshot price$154.1as of page date

Monthly-close return+63.8%five-year window

FY2025 revenue$2.86BNEUROCRINE BIOSCIENCES INC

Net margin16.7%FY2025

P/E snapshot22.5xone ratio, not a verdict

Prism attention2.1%share across these five

Filing track recordRevenue, USD billions

+152.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 26.0%

52-week position50% through range

$122.1$186.1

News mentions2.8K

Community mentions0partial coverage

U.S.-scope patents1228

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal79/100
Management stability90/100
Market position8/100
Capital-event signal70/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4AMGN · Nasdaq

Amgen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1980WILMINGTON$233.78B market cap

View full Companies Radar profile

54Moderate

Snapshot price$432.4as of page date

Monthly-close return+93.8%five-year window

FY2025 revenue$36.75BAMGEN INC

Net margin21.0%FY2025

P/E snapshot26.9xone ratio, not a verdict

Prism attention37.2%share across these five

Filing track recordRevenue, USD billions

+41.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.1%

52-week position92% through range

$269.8$447.0

News mentions48.5K

Community mentions2.2Kpartial coverage

U.S.-scope patents21491

Prism InsightsWhat sits behind the readiness signal
Observed risk 9/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position52/100
Capital-event signal50/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 70 M&A involvements, 15 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BIIB · Nasdaq

Biogen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2018Cambridge, Massachusetts$32.28B market cap

View full Companies Radar profile

43Cautious

Snapshot price$218.5as of page date

Monthly-close return-34.6%five-year window

FY2025 revenue$9.89BBIOGEN INC.

Net margin13.1%FY2025

P/E snapshot38.7xone ratio, not a verdict

Prism attention24.2%share across these five

Filing track recordRevenue, USD billions

-9.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.6%

52-week position95% through range

$133.5$222.8

News mentions31.5K

Community mentions4.1Kpartial coverage

U.S.-scope patents7929

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position20/100
Capital-event signal5/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 15 M&A involvements, 4 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Exelixis

+188.3%

Gilead

+104.5%

Amgen

+93.8%

Neurocrine

+63.8%

Biogen

-34.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Amgen

$36.75B

Gilead

$29.44B

Biogen

$9.89B

Neurocrine

$2.86B

Exelixis

$2.32B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Exelixis

33.7%

Gilead

28.9%

Amgen

21.0%

Neurocrine

16.7%

Biogen

13.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Amgen

37.2%

Gilead

34.6%

Biogen

24.2%

Neurocrine

2.1%

Exelixis

1.9%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Amgen leads the conversation

It holds 37.2% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $36.75B.

Price path

Exelixis leads the available price paths

Its monthly-close return is +188.3% for the five-year window. At the other end, Biogen is -34.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Exelixis has the widest latest margin

Its FY2025 net margin is 33.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Gilead shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 14.7x while its five-year window price return is +104.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GILD

Gilead

45,041available Prism news records

Prism top themes

Legal, arbitration & regulatory

268

Capital allocation & transactions

259

Price action & investor response

239

Earnings & financial performance

188

Macro demand & rates

148

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+10.7%5,601 latest 12m vs 5,059 prior 12m

Machine-classified coverage tone

84.5% positive+8.1 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

conceptual rock albums 381genre-defying rock 381narrative-driven rock 380technical rock journeys 380avant-garde rock 380psychedelic textures 380unconventional rock instruments 380mind-expanding rock 380

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-14 · trend and themes shown through 2026-07

Areas of research · EXEL

Exelixis

2,485available Prism news records

Prism top themes

Price action & investor response

108

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-51.1%247 latest 12m vs 505 prior 12m

Machine-classified coverage tone

95.3% positive+2.4 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 58angiogenesis inhibitors 28stock price 28cancer biomarkers 15share price 13earnings report 13stock surge 13annual earnings 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-08-04 · trend and themes shown through 2026-08

Areas of research · NBIX

Neurocrine

2,766available Prism news records

Prism top themes

Price action & investor response

124

Capital allocation & transactions

103

Earnings & financial performance

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.1%512 latest 12m vs 712 prior 12m

Machine-classified coverage tone

93.3% positive+5.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 49treatment-resistant depression studies 37gene therapy rare diseases 36antipsychotic metabolic effects 33antidepressant response rates 30stock price 25depression treatment outcomes 24psychotropic adverse reactions 21

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-19 · trend and themes shown through 2026-06

Areas of research · AMGN

Amgen

48,476available Prism news records

Prism top themes

Price action & investor response

929

Macro demand & rates

917

Earnings & financial performance

569

Capital allocation & transactions

458

Legal, arbitration & regulatory

452

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-26.7%5,347 latest 12m vs 7,297 prior 12m

Machine-classified coverage tone

83.1% positive+0.5 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 443biosimilar approval 308stock performance 267biosimilar efficacy 256biosimilar market entry 249regulatory pathway biosimilars 200angiogenesis inhibitors 169gene therapy rare diseases 148

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-10 · trend and themes shown through 2026-07

Areas of research · BIIB

Biogen

31,471available Prism news records

Prism top themes

Price action & investor response

451

Legal, arbitration & regulatory

341

Earnings & financial performance

326

Capital allocation & transactions

284

Leadership & governance

232

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-41.6%2,729 latest 12m vs 4,669 prior 12m

Machine-classified coverage tone

87.9% positive+3.7 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 263orphan drug pricing 191biosimilar approval 181biosimilar market entry 147biosimilar efficacy 142orphan drug incentives 124regulatory pathway biosimilars 119stock performance 119

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-08-04 · trend and themes shown through 2026-08

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

GILD

Gilead

8,101 mentions

Stock and valuation

3,626

Products, pricing and logistics

2,029

Workplace and hiring

183

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 8,101 records remained after filtering.

AMGN

Amgen

2,234 mentions

Stock and valuation

696

Products, pricing and logistics

516

Workplace and hiring

240

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 2,234 records remained after filtering.

BIIB

Biogen

4,056 mentions

Products, pricing and logistics

1,542

Stock and valuation

1,110

Workplace and hiring

Other company context

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 4,056 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GILD

Gilead

through 2026-04-28

Earnings releases 58M&A 36Leadership changes 15Listing / IPO 9Company announcements 8

2026-04-28
M&A
Gilead completed its acquisition of Arcellx through the merger of Purchaser with and into Arcellx, and without a meeting of the stockholders of Arcellx in accordance with Section 251(h) of the DGCL, with Arcellx surviving such Merger as a wholly owned subsidiary of Gilead.
2026-04-01
Asset acquisitions
Gilead Sciences, Inc. today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.
2026-03-16
Lawsuits
Halper Sadeh LLC is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Arcellx, Inc. (NASDAQ: ACLX )'s sale to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EXEL

Exelixis

through 2026-01-11

Earnings releases 19Listing / IPO 11Leadership changes 9M&A 7Board updates 4

2026-01-11
Earnings releases
Total revenues ~ $2.32 0 billion
2025-02-14
Leadership changes
Exelixis Inc., of South San Francisco, appointed George Poste to its board.
2025-02-14
Business contracts
Exelixis Inc. (EXEL) Merck & Co. Inc. Collaboration for the joint design and generation of small‑molecule compound libraries for high‑throughput drug screening The companies will jointly ... (5/1)

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NBIX

Neurocrine

through 2026-04-12

Earnings releases 50Leadership changes 7Company announcements 6Business contracts 3Listing / IPO 3

2026-04-12
M&A
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has agreed to acquire Soleno Therapeutics, Inc. (NASDAQ: SLNO) for $53.00 per share in cash, valuing the target at about $2.9 billion.
2026-03-22
Company announcements
Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double‑digit volume growth” and record new prescriptions (NRX) across multiple quarters.
2026-03-17
Leadership changes
SAN DIEGO , March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AMGN

Amgen

through 2026-04-29

Earnings releases 43Lawsuits 23Regulatory 17Company announcements 14Leadership changes 8

2026-04-29
Regulatory
First up, the agency has requested—again—that Amgen remove the autoimmune therapy Tavneos from the market. Specifically, the FDA says that unblinded study personnel manipulated results of the pivotal clinical trial that supported the drug’s approval to make it look more effective.
2026-03-02
Earnings releases
Amgen delivered strong performance in 2025, with double‑digit growth in revenues and earnings per share.
2026-01-29
Leadership changes
Katie Casey was promoted to director of corporate affairs for obesity and related conditions communications at Amgen.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BIIB

Biogen

through 2025-02-14

Earnings releases 14M&A 6Asset acquisitions 3Lawsuits 3Business contracts 2

2025-02-14
Leadership changes
Peter Kellogg, executive VP of finance & CFO will leave the organization to become CFO at Merck & Co. Kellogg will leave Biogen Idec on Aug. 10.
2025-02-14
Earnings releases
Biogen Idec said first-quarter 2012 GAAP diluted earnings per share (EPS) were $1.25, an increase of 4 percent over the first quarter of 2011. GAAP net income attributable to the company was $303 million for the quarter, an increase of 3 percent from the same period a year earlier.
2025-02-14
Asset acquisitions
Genentech Inc. is buying Biogen Idec Inc.'s 60-acre biologics manufacturing plant in Oceanside, Calif. - the one that had been slated to make ill-fated Tysabri - for $408 million

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Gilead leads the readiness ranking

Its Prism readiness score is 65/100, the highest in this five-company comparison.

Open Gilead in Companies Radar

Scale and margin leadership sit with Amgen and Exelixis

Amgen has the largest displayed latest revenue at $36.75B; Exelixis has the widest displayed latest margin at 33.7%.

Open Amgen in Companies Radar Open Exelixis in Companies Radar

Comparisons

Strongest versus weakest available price path

Exelixis is +188.3% for its five-year window; Biogen is -34.6% for its five-year window.

Open Exelixis in Companies Radar Open Biogen in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $36.75B for Amgen to $2.32B for Exelixis. Entity and filing-period labels remain visible on the company cards.

Open Amgen in Companies Radar Open Exelixis in Companies Radar

Anomalies

Amgen has the widest attention-readiness rank gap

It ranks #1 by measured news attention (37.2%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Amgen in Companies Radar

Exelixis shows a price-operating divergence to inspect

Its displayed filing-revenue change is +61.7% while its available monthly-close return is +188.3%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open Exelixis in Companies Radar

Explanations

Attention measures coverage volume, not quality

Amgen's 37.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Amgen in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Gilead's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 65/100 score.

Open Gilead in Companies Radar

Stress-test the largest divergence before forming a view

Compare Exelixis's profile with Exelixis's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Exelixis in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.